Showing 1321 - 1330 of 1362 for "ITC litigation" with applied filters
Filters:
16 August 2019 by Chris Adams and Kingsley Egbuonu
In a highly-anticipated biologic patent dispute, the US District Court for the District of New Jersey has found that Amgen's patents for Enbrel® (etanercept) are valid. Two ranked firms are involved in this dispute
12 August 2019 by Margaret Arnott, Harry Rowe and Daniel Ramos
Margaret Arnott, Harry Rowe and Daniel Ramos of Mathys & Squire analyse the UK’s no-deal Brexit plans for EU trade mark and design rights
02 August 2019 by Kingsley Egbuonu
The $1 billion transaction will see Apple acquire “innovative” wireless technology patents from Intel
31 July 2019 by Saya Choudhary Kapur and Vivek Ranjan
Saya Choudhary Kapur and Vivek Ranjan of Singh & Singh Law Firm examine the regulations surrounding medical devices in India and compare the law around patenting methods of treatment with that in the US and Europe
29 July 2019 by Dave A Wyatt
Dave A Wyatt of Henry Goh & Co reviews the recent patent and industrial design trends and developments, including application and registration statistics, the patent prosecution highway (PPH) pilot programme and case law
17 July 2019 by Kingsley Egbuonu
The firm's name partners decided to go their separate ways, with one opting to join a general law firm
23 May 2019 by Lim Eng Leong
Lim Eng Leong of Henry Goh & Co looks back at the trade mark arena in Malaysia in 2018, analysing trade mark growth, administration, legislation and litigation
16 May 2019 by Paul A Ainsworth and Lauren A Watt
Paul A Ainsworth and Lauren A Watt of Sterne Kessler Goldstein & Fox examine the extent to which the proposed Biologic Patent Transparency Act will reduce patent thickets, increase transparency and competition in the biologics industry.
12 December 2018 by Managing Intellectual Property
Managing IP is delighted to announce the launch of its official Rising Stars publication
23 November 2018 by Ilya Kazi
Ilya Kazi and Miranda Kent of Mathys & Squire analyse the changes to the EPO’s opposition procedure and suggest ways in which businesses can align their strategy with the current legal tools available
